At a glance
ClinicalIndex Comparison RecordPhase 2Active· 192 target
Drug / intervention
CT041 autologous CAR T-cell injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04581473Phase 2ActiveUpdate OverdueUpdated 12mo ago · Completion was 20mo agoEnrollment Stalled
An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating CT041 autologous CAR T-cell injection and Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody） for Gastric Adenocarcinoma and 2 related conditions. Active but no longer recruiting, targeting 192 participants across 24 sites.
Signals
Enrollment appears stalled
Detailed Summary
An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Timeline
Phase 2Active
202120222023202420252026202720282029203020312032203320342035203620372038
First PostedOct 2020
Enrollment StartOct 2020
Primary CompletionOct 2024
TodayJul 2026
Study CompletionJun 2038
First PostedOct 9, 2020
Enrollment StartOct 23, 2020
Primary CompletionOct 18, 2024
Study CompletionJun 30, 2038
TodayJul 1, 2026
Enrollment to primary: 4.0 yearsPosted 5.7 years ago
Interventions
CT041 autologous CAR T-cell injectiondrug
Up to 3 times CT041 autologous CAR T-cell injection infusion
Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）drug
Physician's choice of any BSC listed above